Updated Instructions: Seeking Proposals: Antibacterial Accelerator Bro…
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases.
Together with our industry partners, BARDA promotes the advanced development of medical countermeasures to protect Americans and respond to 21st century health security threats.
STATEMENT FROM THE BARDA DIRECTOR
on the emergency use authorization of Janssen’s COVID-19 Vaccine
Dr. Gary Disbrow, BARDA Director
The mission of the Biomedical Advanced Research and Development Authority (BARDA) is to develop medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases.
BARDA supports a number of core services to assist the development and production of required products, in a manner that is timely, reliable and cost effective.
BARDA's countermeasure development divisions, our Division of Research, Innovation & Ventures (DRIVe), and the TechWatch program help bring innovation to our programs. These programs identify and support the advancement of technologies that enhance capabilities for the development and manufacturing of medical countermeasures focusing on biodefense, pandemic influenza and other emerging infectious diseases.
The Pandemic and All Hazards Preparedness Act (PAHPA) established BARDA as the focal point within HHS for the advanced development of and acquisition of medical countermeasures to protect the American civilian population against CBRN and naturally occurring public health threats.
Congress seeks to improve our Nation's emergency preparedness with Project BioShield, which provides the government with the ability to further develop, acquire, stockpile, and make available the medical countermeasures needed to protect the U.S. population against a public health threat.
BARDA uses a comprehensive portfolio approach to develop and acquire a broad array of medical countermeasures for pandemic influenza, including vaccines, therapeutics, diagnostics, and non-pharmaceutical countermeasures and to build and sustain their domestic manufacturing infrastructure.
BARDA supports a number of core services to assist the development and production of required products, in a manner that is timely, reliable and cost effective.
BARDA's countermeasure development divisions, our Division of Research, Innovation & Ventures (DRIVe), and the TechWatch program help bring innovation to our programs. These programs identify and support the advancement of technologies that enhance capabilities for the development and manufacturing of medical countermeasures focusing on biodefense, pandemic influenza and other emerging infectious diseases.
The Pandemic and All Hazards Preparedness Act (PAHPA) established BARDA as the focal point within HHS for the advanced development of and acquisition of medical countermeasures to protect the American civilian population against CBRN and naturally occurring public health threats.
Congress seeks to improve our Nation's emergency preparedness with Project BioShield, which provides the government with the ability to further develop, acquire, stockpile, and make available the medical countermeasures needed to protect the U.S. population against a public health threat.
BARDA uses a comprehensive portfolio approach to develop and acquire a broad array of medical countermeasures for pandemic influenza, including vaccines, therapeutics, diagnostics, and non-pharmaceutical countermeasures and to build and sustain their domestic manufacturing infrastructure.
HHS’s first venture capital partnership to develop transformative technologies to combat future pandemics, other health emergencies. This new novel partnership is leveraging venture capital practices to transform health security.
If you are interested in partnering with the federal government on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners.
To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) to support a number of new medical countermeasures to fight the COVID-19 outbreak.
BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003).
